Russia Online Smartphone Sales Highest Ever in Q2 2020
20.8.2020 15:45:00 EEST | Business Wire | Press release
Online smartphone sales in Russia grew by more than 56% YoY during Q2 2020, according to the latest research by Counterpoint Research Model Sales Tracker. The total online smartphone market share reached its highest ever at 32% during Q2 2020. The increase in online channel sales is due to the shift in consumer behaviour, upgrade of devices to work from home smoothly and the availability of popular smartphones on online platforms. The COVID-19 pandemic had a huge impact on the Russian smartphone market. After seeing a record decline in April, it bounced back in May. Top five smartphone brands — Huawei, Samsung, Xiaomi, Apple and OPPO — accounted for 86% of the total smartphone market during this quarter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200820005479/en/
Russia Online Smartphone Market Share by Channel – Q2 2020 (Graphic: Business Wire)
Commenting on the market dynamics, Research Associate Soumen Mandal said: “M.Video-Eldorado and Svyaznoy are leading players among online smartphone platforms while Citilink, Megafone, Beeline, MTS and DNS are emerging players. More than one-third of smartphone sales happened on the M.Video-Eldorado platform during Q2 2020. The balanced operation between online and offline platforms and promotional activities helped M.Video-Eldorado to maintain a dominating position in online channel sales.”
Mandal added: “Small players like Black Fox, CAT, Ginzzu, Dexp and Coolpad are still relying on offline channel sales. Among the top five smartphone players, Apple is the most dependent (74%) on offline channel sales. The average cost of a smartphone purchased from an online channel increased by 15% to reach $210 during Q2 2020 compared to $182 in Q2 2019. This also shows the recovery of Russian economy from the global pandemic. On offline platforms, the best-selling models are the Samsung Galaxy A51, Honor 8A, Apple iPhone 11, Samsung Galaxy A10 and the Samsung Galaxy A30s.”
Commenting on brand performance, Associate Director Tarun Pathak said: “Huawei remained the market leader in online channel sales with 35% market share. Samsung Galaxy A51 was the top model for online channel sales, followed by the Honor 8A, Honor 20 Lite, Honor 10i and the Apple iPhone 11. Xiaomi took the third position in online channel sales after Huawei and Samsung.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200820005479/en/
Contact information
Analyst Contacts:
Soumen Mandal
soumen@counterpointresearch.com
Tarun Pathak
tarun@counterpointresearch.com
Counterpoint Research
press@counterpointresearch.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom